Liquid Biopsy Global Products and Practices: Instrumentation, Ancillaries, Kits, Consumables, Reagents, Methods, Applications and Clients

 
 
$1,831.21/ £1,408.62 
Date:14/05/2018
Pages:187
Customer Support
+44 (0)1487 843 722

If you have any questions, please
call and we will gladly assist.

Chat with the Author
Call +44 (0)1487 843 722
 
Untitled Document

Summary

This market study provides a detailed analysis of laboratory products being used in the liquid biopsy field. These areas include instrumentation, ancillary equipment and systems, kit-based products, assays, consumables, reagents and others. The products profiled relate to all liquid biopsy strategies including circulating tumour cells, exosomes, circulating cell-free DNA (cfDNA), circulating cell-free tumour DNA (ctDNA) and other circulating genetic markers being explored in this field. These products are classified by company suppliers, product names, methods areas and by their applications in the liquid biopsy field. Overall, the study identified 128 company suppliers, 449 individual products by name, 195 method areas and 186 applications relating to liquid biopsy.

The report provides a competitive analysis across all of these product areas in the liquid biopsy field, covering global regions, countries and organisations types (e.g. hospitals, companies and institutes etc) as well as the names of the organisations profiled in this study. In carrying out this market analysis, we profiled over 700 methodology approaches and the associated products used, across all areas of the liquid biopsy field. We also used these findings to develop an extensive study file of more than 1500 organisations globally, where liquid biopsy is used. Our findings also enabled us to determine future liquid biopsy users in the years ahead and these findings (i.e. organisation names, countries etc) are also provided with the report as a source of qualified market leads to report purchasers.

Companies Mentioned

Liquid Biopsy Global Product Analysis covered products supplied by 128 companies that supply laboratory products used in the liquid biopsy field. These products included all cited consumables and reagents (e.g. chemicals, antibodies etc.,), all-in-one isolation kits (e.g. CTC, cfDNA, ctDNA, assays etc) and equipment or instrumentation (e.g. used in CTC, exosome or cell-free nucleic acid analysis, isolation, sample preparation, imaging etc.). These companies related to 449 individual products by name in 195 method areas and 186 applications relating to liquid biopsy. Example companies include Abbott Molecular, AdnaGen, Applied Biosystems, Axygen, BD Biosciences, Beckman Coulter, Becton Dickinson, ClearBridge Biomedics, Janssen, Macherey-Nagel, Systems Biosciences and Thermo Fisher Scientific.

Purpose of Market Study

This market study was carried out to identify new opportunities to suppliers in the liquid biopsy field. Its findings enable supplier to extend the reach of their existing products, as well as identify new market needs. The second, and we believe the most important goal of this study, is to enable suppliers to predict where the greatest developments and opportunities will be found in the liquid biopsy field in the coming years.

'Liquid Biopsy Global Product Analysis' was carried out in two phases. The first phase involved a detailed analysis of current and evolving liquid-biopsy liquid biopsy current practices from reagent level upwards. The second phase used this information to identify where the greatest developments in the liquid biopsy field will take place over the next few years. The study file compiled during this study is also supplied to purchasers, alongside the PDF market report.

Market Areas

Global Regions

This market study was carried out in two phases, 1 and 2. Phase 1 of this study (see Purpose of Study) covered 7 regions, namely Asia, Europe, Middle East, North America, Northern Africa, Oceania, South America and Southern Africa and the data are also analysed across major regions too, namely the Americas, EMEA and Asia Pacific. This analysis was based on over 700 liquid biopsy methodology approaches cited by end-users (covering 128 laboratory suppliers, 449 individual products by name, 195 method areas and 186 applications relating to liquid biopsy. In Phase 2 of this study (see Purpose of Study), we used the information obtained on phase 1 in which we used the information obtained in Phase 1 to identify leading market areas and where the greatest market opportunities liquid biopsy field are anticipated to be found over the next few years. We covered the same regions and major regions, while in this case more than 1500 end-user organisations were identified. The compiled study files relating to liquid biopsy end-users in both phases of this study are provided to purchasers alongside the PDF market report.

Countries

Phase 1 of this study (see Purpose of Study) covered 37 countries including United States, China, Japan, Germany, Australia, UK, Spain, South Korea, Italy, Sweden, Canada, France, Greece and Poland. In Phase 2 of this study our analysis covered more than 40 countries, which included all 'top market ranking' countries identified in Phase 1 of our study.

Organisation Types

Phase 1 of this study (see Purpose of Study) covered 18 organisation types including hospitals, institutes, universities, companies, medical centres and others. In Phase 2 of this study our analysis covered more than 25 organisation types, which included all 'top market ranking' organisation types identified in Phase 1 of our study.

Circulating Tumour Cells

In Phase 1 of this study (see Purpose of Study) our analysis covered all identified methods and practices relating to the isolation, enrichment, identification, analysis and the study of CTCs in the context of liquid biopsies. In Phase 2 of this study our analysis covered all organisations working with CTCs, as well as other 'top ranking' market areas, identified in Phase 1 of our study.

Exosomes

In Phase 1 of this study (see Purpose of Study) our analysis covered all identified methods and practices relating to the isolation, enrichment, identification, analysis and study of exosomes in the context of liquid biopsies. In Phase 2 of this study our analysis covered all organisations working with exosomes, as well as other 'top ranking' market areas, identified in Phase 1 of our study.

Circulating Cell-Free Nucleic Acids

In Phase 1 of this study (see Purpose of Study) our analysis covered all identified methods and practices relating to the isolation, enrichment, identification, analysis and study of circulating cell-free nucleic acids (cfDNA, cfRNA, ctDNA and others) in the context of liquid biopsies. In Phase 2 of this study our analysis covered all organisations working with circulating cell-free nucleic acids (cfDNA, cfRNA, ctDNA and others), as well as other 'top ranking' market areas, identified in Phase 1 of our study.

Laboratory Suppliers

Our study identified and profiled (by product, method area, applications and other areas) 128 companies that supply products relating to liquid biopsies. These companies cover all of the product areas evaluated in this study including instrumentation, ancillary equipment and systems, kit-based products, assays, reagents and consumables.

Products

This market study provides a detailed analysis of laboratory products (449 identified) that are area being used in the liquid biopsy field. These product areas include instrumentation, ancillary equipment and ancillary systems, kit-based products in all areas and consumables from reagent levels upwards.

Method Areas

This market study carried out a detailed analysis of the method areas relating to the liquid biopsy products profiled in this study. This market analysis identified 195 methodology areas, which were also segmented by application and other sectors covered in this study.

Applications

This market study carried out a detailed analysis of the application areas relating to the liquid biopsy method areas profiled in this study. This market analysis identified 186 applications, which were also segmented by methods and other sectors covered in this study.

Drug R&D

As part of the market analysis carried out in this study, we also analysed the use of liquid biopsy interventions in clinical trials, where these techniques are incorporated as part of the clinical protocols. This identified 448 clinical trials, of which 179 are being progressed by (primarily pharmaceutical and diagnostic) companies. This part of the study included all of the current liquid biopsy methodologies identified earlier in this study (CTCs, exosomes circulating cell-free nucleic acids) and covered clinical trial phase and start dates, which has allowed the growth (numbers of trials) in this sector to be calculated.

Diagnostics

Diagnostics is at the heart of the liquid biopsy field and this study identified diagnostics companies both as suppliers into laboratories and involved in the conduct of clinical trials in this field. These companies have also been segmented across all other areas of the study, notably relating to CTCs, exosomes, circulating cells-free nucleic acids, methods and applications.

Antibodies

Antibodies are very vitally important in the liquid biopsy field, for many different reasons. As part of this study antibodies have been covered in some depth, with 53 different antibodies (21 companies) and 22 conjugated antibodies (10 companies) identified. This antibodies and conjugated antibodies have also been segmented across all other areas of the study, notably relating to CTCs, exosomes, circulating cells-free nucleic acids, methods and applications.

Imaging

Imaging is also important in the liquid biopsy field and as part of this study imaging has been covered this in some depth, where we identified 26 companies and 46 products, systems or platforms or ancillaries. Imaging methods have also been segmented across all other areas of the study, notably relating to CTCs, exosomes, circulating cells-free nucleic acids, methods and applications.

Market Opportunities

The identification of market opportunities was a key goal in the conduct of this market study. Findings relating to opportunities were made through the detailed stratification of products, methods and applications relating to CTCs, exosomes and circulating nucleic acids, which identified where and how these products are being used. Phase 2 of this study also identified more than 1500 end-user organisations in the liquid biopsy field, providing a valuable source of market prospects to suppliers.

Future Use

The future anticipated use liquid biopsy methodologies was analysed in Phase 2 of this study, which used the findings compiled in Phase I to identify the top users globally. This covered the major sectors of the liquid biopsy field, including CTCs, exosomes and circulating cell-free nucleic acids.

Market Growth

The future anticipated use liquid biopsy methodologies was also analysed in Phase 2 of this study, which used the findings compiled in Phase I to identify the top users globally. This covered the major sectors of the liquid biopsy field, including CTCs, exosomes and circulating cell-free nucleic acids.

Clients

As part of Phase 1 and Phase 2 of this study, we identified liquid biopsy end-users by organisation name. These are segmented globally and by country and across all other areas of the study, enabling specific activities in this field to be directly linked to the organisations themselves. The compiled data files of phases 1 and 2 of this study are provided to purchasers alongside the PDF market report.

 

 

 

  •